Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | TET3 | O43151 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | FBXL19 | Q6PCT2 | 4/20 | 0.42 |
| ▸ | CXXC5 | Q7LFL8 | 4/20 | 0.42 |
| ▸ | KDM2B | Q8NHM5 | 4/20 | 0.42 |
| ▸ | CXXC4 | Q9H2H0 | 4/20 | 0.42 |
| ▸ | KDM2A | Q9Y2K7 | 4/20 | 0.42 |
| ▸ | TET1 | Q8NFU7 | 3/20 | 0.42 |
| ▸ | ACHE | P22303 | 7/20 | 0.39 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.37 |
| ▸ | TEAD1 | P28347 | 3/20 | 0.36 |
| ▸ | TEAD3 | Q99594 | 2/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31562056 | 0.87 | MAPK1 (0.49) | MAPK1TET3KMT2AFBXL19CXXC5 | |
| SCHEMBL12764449 | 0.83 | TET3 (0.47) | MAPK1TET3KMT2AFBXL19CXXC5 | |
| SCHEMBL20547259 | 0.83 | TET3 (0.47) | MAPK1TET3KMT2AFBXL19CXXC5 | |
| SCHEMBL167151 | 0.83 | TET3 (0.47) | MAPK1TET3KMT2AFBXL19CXXC5 | |
| SCHEMBL237862 | 0.83 | — | — | |
| SCHEMBL24160991 | 0.77 | POLB (0.35) | KMT2A | |
| SCHEMBL31561985 | 0.76 | — | — | |
| Vinyl Chloride SCHEMBL11122339 | 0.75 | TET3 (0.43) | MAPK1TET3KMT2AFBXL19CXXC5 | |
| SCHEMBL149678 | 0.75 | — | — | |
| SCHEMBL505654 | 0.75 | ALDH1A1 (0.48) | MAPK1TET3KMT2AFBXL19CXXC5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6337128-B1 | FOR ADHESION OF GLASS, TILES | NITTO DENKO CORPORATION (JP) | 2002-01-08 | — | — | US | claimed |
| US-12570655-B2 | Cysteine covalent modifiers of AKT1 and uses thereof | TERREMOTO BIOSCIENCES, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| WO-2025081045-A9 | CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| WO-2025217330-A1 | CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| WO-2025217336-A1 | CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| US-20250289819-A1 | CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. | 2025-09-18 | — | — | US | disclosed |
| WO-2025081045-A1 | CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| US-11925651-B2 | TEAD inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2024-03-12 | — | — | US | disclosed |
| CN-112341959-B | Adhesive composition, adhesive layer, and adhesive film | DIC株式会社 | 2024-01-05 | — | — | CN | disclosed |
| CN-112625622-B | Adhesive composition, adhesive layer and adhesive film | DIC株式会社 | 2023-10-10 | — | — | CN | disclosed |
| EP-3386992-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | Janssen Pharmaceutica, N.V. (BE) | 2018-10-17 | — | — | EP | disclosed |
| WO-2018103058-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-14 | — | — | WO | disclosed |
| WO-2018103058-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-14 | — | — | WO | disclosed |
| US-20170283431-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2017-10-05 | — | — | US | disclosed |
| US-20170283431-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2017-10-05 | — | — | US | disclosed |
| US-20170283431-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2017-10-05 | — | — | US | disclosed |
| WO-2017100668-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-15 | — | — | WO | disclosed |
| WO-2017100668-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-15 | — | — | WO | disclosed |
| US-4567142-A | CHEMICALLY STABILIZED GLUCOSE ISOMERASE | NABISCO BRANDS, INC. (US) | 1986-01-28 | — | — | US | disclosed |
| US-4411996-A | TO FRUCTOSE, CHEMICALLY STABILIZED GLUCOSE ISOMERASE | NABISCO BRANDS, INC. (US) | 1983-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11925651-B2 | TEAD inhibitors and uses thereof | TEAD2, TEAD3, TEAD4 | MAPK1 2346/4885TET3 2248/4885KMT2A 2717/4885 |
| US-12570655-B2 | Cysteine covalent modifiers of AKT1 and uses thereof | AKT1, AKT2, AKT3 | MAPK1 178/4885TET3 3131/4885KMT2A 1229/4885 |
| US-20170283431-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | ABL1, BTK, MYLK2 | MAPK1 385/4885TET3 3156/4885KMT2A 2626/4885 |
| US-20250289819-A1 | CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF | AKT1, AKT2, AKT3 | MAPK1 165/4885TET3 3108/4885KMT2A 932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.